Table 1. Drug resistance to non-β-lactams and presence of virulence genes in CC59 S. aureus strains.
| No. (%) of strains | |||
|---|---|---|---|
| SCCmec IV (n = 91) | SCCmec V (5C2&5) (n = 74) | MSSA (n = 30) | |
| Drug resistance rate (%) | |||
| Erythromycin | 85 (93.4) | 66 (89.2) | 27 (90.0) |
| Kanamycin | 80 (87.9) | 66 (89.2) | 27 (90.0) |
| Streptomycin a | 20 (22.0) | 66 (89.2) | 25 (83.3) |
| Gentamicin a | 58 (63.7) | 2 (2.7) | 3 (10.0) |
| Chloramphenicol | 60 (65.9) | 46 (62.2) | 16 (53.3) |
| Susceptible to above antibiotics | 3 (3.3) | 6 (8.0) | 3 (10.0) |
| Presence of virulence genes (%) | |||
| lukPVSF b | 12 (13.2) | 71 (95.9) | 15 (50.0) |
| hlb c | 80 (87.9) | 74 (100) | 30 (100) |
| Immune evasion cluster (IEC) | |||
| Type B: sak, chp, scn c | 13 (14.3) | 0 (0) | 1 (3.3) |
| Type C: chp, scn b | 8 (8.8) | 74 (100) | 25 (83.3) |
| Type D: sea, sak, scn | 3 (3.3) | 0 (0) | 0 (0) |
| Type G: sep, sak, scn b | 63 (69.2) | 0 (0) | 4 (13.3) |
| No IEC | 4 (4.4) | 0 (0) | 0 (0) |
a Statistically significant difference between SCCmec IV MRSA/SCCmec V (5C2&5) MRSA and between SCCmec IV MRSA/MSSA.
b Statistically significant difference among SCCmec IV MRSA, SCCmec V (5C2&5) MRSA and MSSA.
c Statistically significant difference between SCCmec IV MRSA/SCCmec V (5C2&5) MRSA.